Savara (also known as Savara Pharmaceuticals) is an orphan lung disease company. It offers Molgradex, a product that is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company also develops AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.
Type | Public | |
Founded | 1995 | |
HQ | Austin, TX, US | Map |
Website | savarapharma.com |
Market capitalization (1-Mar-2021) | 98.5m |
Closing stock price (1-Mar-2021) | 1.8 |
Savara has 582 Twitter Followers. The number of followers has increased 0.6% month over month and increased 1.1% quarter over quarter
When was Savara founded?
Savara was founded in 1995.
Who are Savara key executives?
Savara's key executives are Matthew Pauls, Dave Lowrance and Badrul Chowdhury.
How many employees does Savara have?
Savara has 39 employees.
Who are Savara competitors?
Competitors of Savara include Lung Biotechnology, NanoViricides and ANP Technologies.
Where is Savara headquarters?
Savara headquarters is located at 6836 Bee Caves Rd Building 3, Suite 200, Austin.
Where are Savara offices?
Savara has offices in Austin and Hørsholm.
How many offices does Savara have?
Savara has 2 offices.
Receive alerts for 300+ data fields across thousands of companies